株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の免疫チェックポイント阻害薬市場の分析

Global Market Study on Immune Checkpoint Inhibitors: Programmed Death Protein 1 (PD-1) Drug Class to Dominate in Terms of Value Through 2026

発行 Persistence Market Research 商品コード 707216
出版日 ページ情報 英文 208 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.36円で換算しております。
Back to Top
世界の免疫チェックポイント阻害薬市場の分析 Global Market Study on Immune Checkpoint Inhibitors: Programmed Death Protein 1 (PD-1) Drug Class to Dominate in Terms of Value Through 2026
出版日: 2018年08月23日 ページ情報: 英文 208 Pages
担当者のコメント
本庶佑氏のノーベル医学生理学賞で大きく話題となっている免疫チェックポイント阻害のレポートです。
概要

世界の免疫チェックポイント阻害薬市場は、2018年から2026年にかけて14.6%のCAGRで推移することが予測されています。

当レポートでは、世界の免疫チェックポイント阻害薬市場について調査し、市場の概要、薬物クラス・治療分野・流通経路・地域・国別の市場規模の推移と予測(過去5年間、今後8年間分)、場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 市場の定義
  • 市場の分類

第3章 市場機会の分析

  • マクロ経済要因
  • 市場機会の分析

第4章 市場背景

  • メーカー一覧
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場動向

第5章 主な内容

  • 世界の製薬業界の展望
  • サプライチェーン
  • パイプライン分析
  • 償還シナリオ
  • 参入企業の市場プレゼンスと承認・規制動向:地域別

第6章 北米の免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:国別(実績値・予測値)
    • 米国
    • カナダ
  • 市場規模:薬物クラス別(実績値・予測値)
    • PD-1
    • PD-L1
    • CTLA-4
  • 市場規模:治療分野別(実績値・予測値)
    • 肺癌
    • 黒色腫
    • 尿路上皮癌
    • 扁平上皮癌
    • 血液腫瘍
    • その他
  • 市場規模:流通経路別(実績値・予測値)
    • 病院薬局
    • 小売薬局
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第7章 ラテンアメリカの免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:国別(実績値・予測値)
    • アルゼンチン
    • ブラジル
    • メキシコ
  • 市場規模:セグメント別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第8章 欧州の免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:国別(実績値・予測値)
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • その他
  • 市場規模:セグメント別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第9章 アジア太平洋の免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:国別(実績値・予測値)
    • 中国
    • インド
    • オーストラリア・ニュージーランド
    • ASEAN
    • その他
  • 市場規模:セグメント別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第10章 日本の免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:セグメント別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第11章 中東・アフリカの免疫チェックポイント阻害薬市場

  • イントロダクション
  • 市場規模:国別(実績値・予測値)
    • 湾岸協力会議(GCC)
    • 南アフリカ
    • その他
  • 市場規模:セグメント別(実績値・予測値)
  • 市場魅力分析:セグメント別
  • 成長要因と阻害要因:影響力の分析

第12章 予測要因:関連性と影響力

第13章 予測の仮定

第14章 市場構造分析

  • 市場構造:企業層別
  • トッププレーヤーの市場シェア分析(2017)
  • トッププレーヤーの主要な開発分析

第15章 競争分析

  • コンペティションダッシュボード
  • 企業プロファイル
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Co.
    • Roche Holding AG
    • Incyte Corporation
    • Merck & Co., Inc.
    • Merck KGaA
    • Sanofi
    • Novartis AG

第16章 世界の免疫チェックポイント阻害薬市場:地域別

第17章 世界の免疫チェックポイント阻害薬市場:薬物クラス別

第18章 世界の免疫チェックポイント阻害薬市場:治療分野用

第19章 世界の免疫チェックポイント阻害薬市場:流通経路別

第20章 市場分析と予測

  • 市場規模の分析:セグメント別
  • 前年比成長率の分析:セグメント別

第21章 調査方法

図表

List of Tables

  • Table 01: List of Key Immune Checkpoint Inhibitor Manufacturers
  • Table 02: Number of FDA Approvals (2010-2017)
  • Table 03: Bristol-Myers Squib Immune Checkpoint Inhibitors Pipeline
  • Table 04: AstraZeneca Immune Checkpoint Inhibitors Pipeline
  • Table 05: Roche Holdings AG Immune Checkpoint Inhibitors Pipeline
  • Table 06: Merck KgaA Immune Checkpoint Inhibitors Pipeline
  • Table 07: Others Immune Checkpoint Inhibitors Pipeline
  • Table 08: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 09: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 10: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 11: North America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 12: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 13: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 14: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 15: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 16: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 17: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 18: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 19: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 20: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 21: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 22: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 23: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 24: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 25: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 25: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channe6
  • Table 27: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 28: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class
  • Table 29: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application
  • Table 30: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 31: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013-2016 and Forecast 2017-2026, By Region
  • Table 32: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013-2016 and Forecast 2017-2026, By Drug Class
  • Table 33: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013-2016 and Forecast 2017-2026, By Therapeutic Applications
  • Table 34: Global Immune Checkpoint Inhibitors Market size (US$ Mn) Analysis 2013-2016 and Forecast 2017-2026, By Distribution Channel

List of Figures

  • Figure 1: Immune Checkpoint Inhibitor Market Share By Drug Class (2017)
  • Figure 2: Immune Checkpoint Inhibitor Market Share By Therapeutic Application (2017)
  • Figure 3: Immune Checkpoint Inhibitor Market Share By Distribution Channel (2017)
  • Figure 4: Immune Checkpoint Inhibitor Market Share By Region (2017)
  • Figure 5: Global Immune Checkpoint Inhibitor Market Value (US$ Mn) Forecast 2018 and 2026
  • Figure 06: Global Healthcare Expenditure in US$ Tn (2013-2020)
  • Figure 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021
  • Figure 08: Number of FDA approved pharmaceuticals (2010-2017)
  • Figure 09: Pipeline Analysis Based on Company (2017)
  • Figure 10: Pipeline Analysis Based on Phase (2017)
  • Figure 11: Pipeline Analysis Based on API (2017)
  • Figure 12: Pipeline Analysis Based on Target (2017)
  • Figure 13: Pipeline Analysis Based on Therapeutic Area (2017)
  • Figure 14: Bristol-Myers Squib Pipeline Analysis Based on Therapeutic Indication (2017)
  • Figure 15: Bristol-Myers Squib Pipeline Analysis Based on Phase (2017)
  • Figure 16: Bristol-Myers Squib Pipeline Analysis Based on API (2017)
  • Figure 17: Bristol-Myers Squib Pipeline Analysis Based on Target (2017)
  • Figure 18: AstraZeneca Pipeline Analysis Based on Therapeutic Indication (2017)
  • Figure 19: AstraZeneca Pipeline Analysis Based on Phase (2017)
  • Figure 20: AstraZeneca Pipeline Analysis Based on API (2017)
  • Figure 21: AstraZeneca Pipeline Analysis Based on Target (2017)
  • Figure 22: Pipeline Analysis Based on Phase (2017)
  • Figure 23: Pipeline Analysis Based on Therapeutic Indication (2017)
  • Figure 24: Pipeline Analysis Based on Phase (2017)
  • Figure 25: Pipeline Analysis Based on Therapeutic Indication (2017)
  • Figure 26: Pipeline Analysis Based on Therapeutic Indication (2017)
  • Figure 27: Pipeline Analysis Based on Phase (2017)
  • Figure 28: Pipeline Analysis Based on API (2017)
  • Figure 29: Pipeline Analysis Based on Target (2017)
  • Figure 30: North America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 31: North America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018-2026, by Country
  • Figure 32: U.S. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 33: Canada Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 34: North America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 35: North America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 36: North America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 37: North America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 38: North America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 39: North America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 40: North America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 41: North America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 42: North America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 43: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 44: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 45: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • Figure 46: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 47: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 48: North America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 49: Latin America Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 50: Latin America Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018-2026, by Country
  • Figure 51: Brazil Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 52: Mexico Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 53: Rest of Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 54: Latin America PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 55: Latin America PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 56: Latin America CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 57: Latin America Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 58: Latin America Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 59: Latin America Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 60: Latin America Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 61: Latin America Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 62: Latin America Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 63: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 64: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 65: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • Figure 66: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 67: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 68: Latin America Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 69: Europe Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 70: Europe Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018-2026, by Country
  • Figure 71: U.K. Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 72: Germany Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 73: Russia Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 74: France Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 75: Italy Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 76: Spain Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 77: Rest of Europe Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 78: Europe PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 79: Europe PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 80: Europe CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 81: Europe Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 82: Europe Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 83: Europe Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 84: Europe Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 85: Europe Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 86: Europe Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 87: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 88: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 89: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • Figure 90: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 91: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 92: Europe Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 93: APEJ Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 94: APEJ Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018-2026, by Country
  • Figure 95: India Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 96: China Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 97: Australia & New Zealand Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 98: ASEAN Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 99: Rest of APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 100: APEJ PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 101: APEJ PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 102: APEJ CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 103: APEJ Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 104: APEJ Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 105: APEJ Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 106: APEJ Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 107: APEJ Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 108: APEJ Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 109: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 110: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 111: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • Figure 112: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 113: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 114: APEJ Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 115: Japan Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 116: Japan PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 117: Japan PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 118: Japan CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 119: Japan Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 120: Japan Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 121: Japan Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 122: Japan Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 123: Japan Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 124: Japan Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 125: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 126: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 127: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 128: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 129: Japan Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 130: MEA Immune Checkpoint Inhibitors Market Size (US$ Mn), 2018-2026
  • Figure 131: MEA Immune Checkpoint Inhibitors Market Y-o-Y Growth (%), 2018-2026, by Country
  • Figure 132: GCC Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 133: South Africa Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 134: Rest of MEA Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 135: MEA PD-1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 136: MEA PD-L1 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 137: MEA CTLA-4 Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 138: MEA Lung Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 139: MEA Melanoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 140: MEA Squamous Cell Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 141: MEA Urothelial Carcinoma Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 142: MEA Blood Cancer Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 143: MEA Other Cancers Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 144: Hospital Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 145: Retail Pharmacies Immune Checkpoint Inhibitors Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2026
  • Figure 146: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Country
  • Figure 147: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Drug Class
  • Figure 148: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Therapeutic Application
  • Figure 149: MEA Immune Checkpoint Inhibitors Market Attractiveness Analysis, By Distribution Channel
  • Figure 150: Key Developments, By type of Development
  • Figure 151: Key Developments, By Year
  • Figure 152: Key Developments, By Company
  • Figure 153: Key Development Snapshot, by Type of Development
  • Figure 154: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Region, 2018 & 2026
  • Figure 155: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Region, 2018-2026
  • Figure 156: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Region, 2018-2026
  • Figure 157: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Drug Class, 2018 & 2026
  • Figure 158: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Drug Class, 2018-2026
  • Figure 159: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Drug Class, 2018-2026
  • Figure 160: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Therapeutic Application, 2018 & 2026
  • Figure 161: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Therapeutic Application, 2018-2026
  • Figure 162: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Therapeutic Application, 2018-2026
  • Figure 163: Global Immune Checkpoint Inhibitors Market Share Analysis (%) By Distribution Channel, 2018 & 2026
  • Figure 164: Global Immune Checkpoint Inhibitors Market Y-o-Y Growth (%) By Distribution Channel, 2018-2026
  • Figure 165: Global Immune Checkpoint Inhibitors Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 166: Global Immune Checkpoint Inhibitors Market Value Analysis and Forecast, 2016-2025 (US$ Mn)
  • Figure 167: Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2013-2017
  • Figure 168: Global Immune Checkpoint Inhibitors Market Absolute $ Opportunity (US$ Mn), 2017-2026
目次

Persistence Market Research (PMR) offers an 8-year forecast on the global immune checkpoint inhibitors market. The primary objective of the report is to offer updates and information related to market opportunities in the global immune checkpoint inhibitors market.

Report Description

In terms of revenue, the global immune checkpoint inhibitors market is expected to register a CAGR of 14.6% during the forecast period, 2018-2026. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global immune checkpoint inhibitors market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global immune checkpoint inhibitors market are presented in the report.

The global market for immune checkpoint inhibitors is expected to witness high growth in terms of value in high economic countries due to fast FDA approvals for novel and innovative immune checkpoint inhibitors through combination therapy coupled with growing adoption of immune checkpoint inhibitors for cancer treatment. Additionally, increasing investments in the research and development sector for the approval of immune checkpoint inhibitors for other cancer applications is also expected to drive the growth of the market for immune checkpoint inhibitors.

The report includes immune checkpoint inhibitors, such as PD-1, PD-L1 and CTLA-4. The same are considered for the calculation of total revenue generated by companies by immune checkpoint inhibitors. Currency fluctuations and inflation are not considered while calculating the revenue of the immune checkpoint inhibitors market

The revenue from the immune checkpoint inhibitors market in Asia Pacific is expected to expand at the relatively higher CAGR due to growing adoption of drugs and therapies for cancer and increased approvals of immune checkpoint inhibitors in the region. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the drug class, therapeutic application, distribution channel and regions. The report provides analysis of the global immune checkpoint inhibitors market in terms of market value (US$ Mn).

The global immune checkpoint inhibitors market is segmented on the basis of drug class into:

  • PD-1
  • PD-L1
  • CTLA-4

The report begins with the market definition of immune checkpoint inhibitors, followed by definitions of the different drug class. The market dynamics section includes PMR's analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global immune checkpoint inhibitors market.

The report analyzes the immune checkpoint inhibitors market on the basis of therapeutic application and distribution channel and presents forecast in terms of value for the next 8 years. On the basis of therapeutic application, the global immune checkpoint inhibitors market is segmented into:

  • Lung Cancer
  • Melanoma
  • Squamous Cell Carcinoma
  • Urothelial Carcinoma
  • Blood cancer
  • Other Cancers

On the basis of the distribution channel, the global immune checkpoint inhibitors market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies

Next, the report analyzes the market on the basis of regions and presents forecast in terms of value for the next 8 years. On the basis of region, the global canine arthritis treatment market is segmented into:

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • Russia
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Australia & New Zealand
  • ASEAN
  • Rest of APEJ
  • Japan
  • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

In addition, we have considered year-on-year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global immune checkpoint inhibitors market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the canine arthritis treatment market. To understand the key segments in terms of their growth and performance in the global immune checkpoint inhibitors market, Persistence Market Research has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in immune checkpoint inhibitors market.

In the final section of the report, the 'competitive landscape' has been included to provide a dashboard view of the key companies operating in the global immune checkpoint inhibitors market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the immune checkpoint inhibitors market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global immune checkpoint inhibitors market.

Detailed profiles of immune checkpoint inhibitors drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the immune checkpoint inhibitors market are Bristol-Myers Squibb, AstraZeneca, Merck KGaA, Merck & Co, Novartis AG, Sanofi, Roche Holdings AG, Incyte Corporation, among others.

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Immune Checkpoint Inhibitors Market Opportunity Analysis

  • 3.1. Macro-Economic Factors
  • 3.2. Opportunity Analysis

4. Market Background

  • 4.1. List of Manufacturers
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Trends

5. Key Inclusions

  • 5.1. Global Pharmaceutical Industry Outlook
  • 5.2. Supply Chain
  • 5.3. Pipeline Analysis
  • 5.4. Reimbursement Scenario
  • 5.5. Key Participants Market Presence and Regulatory Approvals, By Region

6. North America Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013-2017
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 6.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 6.4.1. PD-1
    • 6.4.2. PD-L1
    • 6.4.3. CTLA-4
  • 6.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 6.6. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Application, 2013-2017
    • 6.6.1. Lung Cancer
    • 6.6.2. Melanoma
    • 6.6.3. Urothelial Carcinoma
    • 6.6.4. Squamous Cell Carcinoma
    • 6.6.5. Blood Cancer
    • 6.6.6. Other Cancers
  • 6.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 6.8.1. Hospital Pharmacies
    • 6.8.2. Retail Pharmacies
  • 6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 6.10. Market Attractiveness Analysis
    • 6.10.1. By Country
    • 6.10.2. By Drug Class
    • 6.10.3. By Therapeutic Application
    • 6.10.4. By Distribution Channel
  • 6.11. Drivers and Restraints - Impact Analysis

7. Latin America Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013-2017
    • 7.2.1. Argentina
    • 7.2.2. Brazil
    • 7.2.3. Mexico
    • 7.2.4. Rest of Latin America
  • 7.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 7.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 7.4.1. PD-1
    • 7.4.2. PD-L1
    • 7.4.3. CTLA-4
  • 7.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 7.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 7.6.1. Lung Cancer
    • 7.6.2. Melanoma
    • 7.6.3. Urothelial Carcinoma
    • 7.6.4. Squamous Cell Carcinoma
    • 7.6.5. Blood Cancer
    • 7.6.6. Other Cancers
  • 7.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 7.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013-2017
    • 7.8.1. Hospital Pharmacies
    • 7.8.2. Retail Pharmacies
  • 7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 7.10. Market Attractiveness Analysis
    • 7.10.1. By Country
    • 7.10.2. By Drug Class
    • 7.10.3. By Therapeutic Application
    • 7.10.4. By Distribution Channel
  • 7.11. Drivers and Restraints - Impact Analysis

8. Europe Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013-2017
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Russia
    • 8.2.7. Rest of Europe
  • 8.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 8.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 8.4.1. PD-1
    • 8.4.2. PD-L1
    • 8.4.3. CTLA-4
  • 8.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 8.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 8.6.1. Lung Cancer
    • 8.6.2. Melanoma
    • 8.6.3. Urothelial Carcinoma
    • 8.6.4. Squamous Cell Carcinoma
    • 8.6.5. Blood Cancer
    • 8.6.6. Other Cancers
  • 8.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 8.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013-2017
    • 8.8.1. Hospital Pharmacies
    • 8.8.2. Retail Pharmacies
  • 8.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 8.10. Market Attractiveness Analysis
    • 8.10.1. By Country
    • 8.10.2. By Drug Class
    • 8.10.3. By Therapeutic Application
    • 8.10.4. By Distribution Channel
  • 8.11. Drivers and Restraints - Impact Analysis

9. Asia Pacific Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013-2017
    • 9.2.1. China
    • 9.2.2. India
    • 9.2.3. Australia and New Zealand
    • 9.2.4. ASEAN
    • 9.2.5. Rest of Asia Pacific
  • 9.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 9.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 9.4.1. PD-1
    • 9.4.2. PD-L1
    • 9.4.3. CTLA-4
  • 9.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 9.6. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 9.6.1. Lung Cancer
    • 9.6.2. Melanoma
    • 9.6.3. Urothelial Carcinoma
    • 9.6.4. Squamous Cell Carcinoma
    • 9.6.5. Blood Cancer
    • 9.6.6. Other Cancers
  • 9.7. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 9.8. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013-2017
    • 9.8.1. Hospital Pharmacies
    • 9.8.2. Retail Pharmacies
  • 9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 9.10. Market Attractiveness Analysis
    • 9.10.1. By Country
    • 9.10.2. By Drug Class
    • 9.10.3. By Therapeutic Application
    • 9.10.4. By Distribution Channel
  • 9.11. Drivers and Restraints - Impact Analysis

10. Japan Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 10.2.1. PD-1
    • 10.2.2. PD-L1
    • 10.2.3. CTLA-4
  • 10.3. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 10.3. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 10.3.1. Lung Cancer
    • 10.3.2. Melanoma
    • 10.3.3. Urothelial Carcinoma
    • 10.3.4. Squamous Cell Carcinoma
    • 10.3.5. Blood Cancer
    • 10.3.6. Other Cancers
  • 10.4. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 10.5. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013-2017
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
  • 10.6. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Country
    • 10.7.2. By Drug Class
    • 10.7.3. By Therapeutic Application
    • 10.7.4. By Distribution Channel
  • 10.8. Drivers and Restraints - Impact Analysis

11. Middle East & Africa Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis by Country, 2013-2017
    • 11.2.1. GCC Countries
    • 11.2.2. South Africa
    • 11.2.3. Rest of MEA
  • 11.3. Market Size (US$ Mn) Forecast By Country, 2018-2026
  • 11.4. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 11.4.1. PD-1
    • 11.4.2. PD-L1
    • 11.4.3. CTLA-4
  • 11.5. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 11.5. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 11.5.1. Lung Cancer
    • 11.5.2. Melanoma
    • 11.5.3. Urothelial Carcinoma
    • 11.5.4. Squamous Cell Carcinoma
    • 11.5.5. Blood Cancer
    • 11.5.6. Other Cancers
  • 11.6. Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 11.7. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2017
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Retail Pharmacies
  • 11.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 11.9. Market Attractiveness Analysis
    • 11.9.1. By Country
    • 11.9.2. By Drug Class
    • 11.9.3. By Therapeutic Application
    • 11.9.4. By Distribution Channel
  • 11.10. Drivers and Restraints - Impact Analysis

12. Forecast Factors: Relevance and Impact

13. Forecast Assumptions

14. Market Structure Analysis

  • 14.1. Market Structure by Tier of Companies
  • 14.2. Market Share Analysis (2017) for Top Players
  • 14.3. Key Development Analysis of Top Players

15. Competition Analysis

  • 15.1. Competition Dashboard
  • 15.2. Company Deep Dive
    • 15.2.1. AstraZeneca Plc.
      • 15.2.1.1. Overview
      • 15.2.1.2. Sales Footprint
      • 15.2.1.3. Strategy
    • 15.2.2. Bristol-Myers Squibb Co.
      • 15.2.2.1. Overview
      • 15.2.2.2. Sales Footprint
      • 15.2.2.3. Strategy
    • 15.2.3. Roche Holding AG
      • 15.2.3.1. Overview
      • 15.2.3.2. Sales Footprint
      • 15.2.3.3. Strategy
    • 15.2.4. Incyte Corporation
      • 15.2.4.1. Overview
      • 15.2.4.2. Sales Footprint
      • 15.2.4.3. Strategy
    • 15.2.5. Merck & Co., Inc.
      • 15.2.5.1. Overview
      • 15.2.5.2. Sales Footprint
      • 15.2.5.3. Strategy
    • 15.2.6. Merck KGaA
      • 15.2.6.1. Overview
      • 15.2.6.2. Sales Footprint
      • 15.2.6.3. Strategy
    • 15.2.7. Sanofi
      • 15.2.7.1. Overview
      • 15.2.7.2. Sales Footprint
      • 15.2.7.3. Strategy
    • 15.2.8. Novartis AG
      • 15.2.8.1. Overview
      • 15.2.8.2. Sales Footprint
      • 15.2.8.3. Strategy

16. Global Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026, By Region

  • 16.1. Introduction/Key Findings
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013-2017
  • 16.3. Market Size (US$ Mn) Forecast By Region, 2018-2026
    • 16.3.1. North America
    • 16.3.2. Latin America
    • 16.3.3. Europe
    • 16.3.4. Asia Pacific
    • 16.3.5. China
    • 16.3.6. Middle East & Africa
  • 16.4. Market Attractiveness Analysis by Region

17. Global Immune Checkpoint Inhibitors Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

  • 17.1. Introduction/Key Findings
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis by Drug Class, 2013-2017
    • 17.2.1. PD-1
    • 17.2.2. PD-L1
    • 17.2.3. CTLA-4
  • 17.3. Market Size (US$ Mn) Forecast By Drug Class, 2018-2026
  • 17.4. Market Attractiveness Analysis by Drug Class

18. Global Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026, By Therapeutic Application

  • 18.1. Introduction/Key Findings
  • 18.2. Historical Market Size (US$ Mn) Trend Analysis by Therapeutic Application, 2013-2017
    • 18.7.1. Lung Cancer
    • 18.7.2. Melanoma
    • 18.7.3. Urothelial Carcinoma
    • 18.7.4. Squamous Cell Carcinoma
    • 18.7.5. Blood Cancer
    • 18.7.6. Other Cancers
  • 18.3. Others Market Size (US$ Mn) Forecast By Therapeutic Application, 2018-2026
  • 18.4. Market Attractiveness Analysis by Therapeutic Application

19. Global Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

  • 19.1. Introduction/Key Findings
  • 19.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channel, 2013-2017
    • 19.2.1. Hospital Pharmacies
    • 19.2.2. Retail Pharmacies
  • 19.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2018-2026
  • 19.4. Market Attractiveness Analysis by Distribution Channel

20. Global Immune Checkpoint Inhibitors Market Analysis 2013-2017 and Forecast 2018-2026

  • 20.1. Market Value Share Analysis by All Segment
  • 20.2. Y-o-Y Growth Analysis by All Segment
  • 20.3. Absolute $ Opportunity

21. Research Methodology

Back to Top